Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020)

Scholar Rock Holding's (SRRK) quarterly Non-Current Deffered Revenue came in at $33.2 million in Q4 2020, down 28.6% year-on-year from $46.5 million in Q1 2020, and down 14.32% quarter-over-quarter from $38.7 million in Q3 2020.

Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020) Analysis & Trends

Scholar Rock Holding's Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $33.2 million for Q4 2020.

  • On a quarterly basis, Non-Current Deffered Revenue fell 28.6% year-over-year to $33.2 million in Q4 2020; TTM through Dec 2020 was $33.2 million, a 28.6% decrease from a year earlier, with the FY2020 full-year figure at $33.2 million, down 28.6% from the prior year.
  • Non-Current Deffered Revenue retreated to $33.2 million in Q4 2020 per SRRK's latest filing, from $38.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $46.5 million in Q4 2019 and bottomed at $468000.0 in Q4 2017.
  • The 4-year median for Non-Current Deffered Revenue is $33.8 million (2019), against an average of $28.6 million.
  • Across the five-year window, Non-Current Deffered Revenue soared 9022.86% in 2018 and slipped 28.6% in 2020, its largest moves.
  • Year by year, Non-Current Deffered Revenue stood at $468000.0 in 2017, then surged by 9022.86% to $42.7 million in 2018, then gained by 8.89% to $46.5 million in 2019, then declined by 28.6% to $33.2 million in 2020.
  • Per Business Quant, the three latest SRRK Non-Current Deffered Revenue figures stand at $33.2 million (Q4 2020), $38.7 million (Q3 2020), and $38.1 million (Q2 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Scholar Rock Holding 6.30 Bn 6.30 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 33.19 Mn
Sep 30, 2020 38.74 Mn
Jun 30, 2020 38.12 Mn
Mar 31, 2020 46.11 Mn
Dec 31, 2019 46.49 Mn
Sep 30, 2019 29.73 Mn
Jun 30, 2019 31.24 Mn
Mar 31, 2019 34.43 Mn
Dec 31, 2018 42.70 Mn
Sep 30, 2018 886,000.00
Jun 30, 2018 681,000.00
Dec 31, 2017 468,000.00